Video Experimental Relacionado

Updated: Feb 19, 2026

In Silico Clinical Trials for Cardiovascular Disease

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Ensayos Pivote en Insuficiencia Cardíaca en 2024 - ¡Poniendo la Evidencia en la Práctica Clínica!

Prashant Thandi¹, Akshyaya Pradhan¹, Suresh Kumar Behera²

¹Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

The International journal of angiology : official publication of the International College of Angiology, Inc

|February 18, 2026

Abstract:

The intricate interplay of physiological, psychological, and social factors presents considerable challenges in addressing heart failure. It is imperative to comprehend the epidemiology and pathophysiology, identify predictors and their influence on clinical outcomes, and effectively utilize the diagnostic tools. Such evidence is vital for formulating innovative therapeutic strategies to decelerate the growing heart failure epidemic. As of 2024, the field of heart failure has witnessed significant advancements in therapies applicable to both heart failure with preserved and reduced ejection fraction. Recent studies in this domain yielded valuable insights into the latest developments in cardiovascular medicine, which possess the potential to revolutionize treatment strategies. These advancements advocate for a more integrated approach to patient care and aim to enhance overall clinical outcomes. Below is a concise overview of key studies showcased at scientific meetings over the past year, which promise to improve heart failure management.

Palabras clave:

cardiomiopatía diabética empagliflozina finerenona insuficiencia cardíaca MCH no obstructiva obesidad semaglutida

Más Videos Relacionados

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Videos de Conceptos Relacionados

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Heart Failure III: Clinical Manifestations

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...